Hollencrest Capital Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5K Hold
101
﹤0.01% 824
2025
Q4
$10.6K Hold
101
﹤0.01% 811
2025
Q3
$9.34K Hold
101
﹤0.01% 807
2025
Q2
$8.07K Hold
101
﹤0.01% 804
2025
Q1
$8.75K Hold
101
﹤0.01% 791
2024
Q4
$8.35K Hold
101
﹤0.01% 817
2024
Q3
$8.78K Hold
101
﹤0.01% 774
2024
Q2
$8.3K Hold
101
﹤0.01% 767
2024
Q1
$8.1K Hold
101
﹤0.01% 739
2023
Q4
$7.69K Hold
101
﹤0.01% 754
2023
Q3
$7.31K Hold
101
﹤0.01% 768
2023
Q2
$7.64K Hold
101
﹤0.01% 789
2023
Q1
$7.68K Hold
101
﹤0.01% 786
2022
Q4
$7.94K Buy
+101
New +$7.76K ﹤0.01% 753
2016
Q2
Sell
-22,141
Closed -$1.33M 445
2016
Q1
$1.33M Sell
22,141
-653
-3% -$39.9K 0.23% 84
2015
Q4
$1.59M Buy
+22,794
New +$1.62M 0.28% 80

Other funds holding PJP

Hollencrest Capital Management's PJP Position: Q1 2026 in Review

Hollencrest Capital Management held its Invesco Pharmaceuticals ETF (PJP) position steady in Q1 2026 at 101 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Hollencrest Capital Management first reported a position in PJP in Q4 2015 and has held it in 16 quarters since. The position peaked at $1.59M in Q4 2015. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

  • Hollencrest Capital Management held 101 shares of Invesco Pharmaceuticals ETF worth $10.5K as of Q1 2026.
  • Hollencrest Capital Management left its Invesco Pharmaceuticals ETF share count unchanged in Q1 2026.
  • Invesco Pharmaceuticals ETF made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q1 2026, its #824 holding.
  • Hollencrest Capital Management first reported a position in Invesco Pharmaceuticals ETF in Q4 2015 and has held it in 16 quarters since.
  • Hollencrest Capital Management's Invesco Pharmaceuticals ETF position peaked at $1.59M in Q4 2015.
  • 119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.